220 related articles for article (PubMed ID: 27911294)
1. Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.
Sokolow S; Li X; Chen L; Taylor KD; Rotter JI; Rissman RA; Aisen PS; Apostolova LG
J Alzheimers Dis; 2017; 56(1):229-237. PubMed ID: 27911294
[TBL] [Abstract][Full Text] [Related]
2. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
[TBL] [Abstract][Full Text] [Related]
3. Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine.
Scacchi R; Gambina G; Moretto G; Corbo RM
Am J Med Genet B Neuropsychiatr Genet; 2009 Jun; 150B(4):502-7. PubMed ID: 18780301
[TBL] [Abstract][Full Text] [Related]
4. Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.
Vijayaraghavan S; Darreh-Shori T; Rongve A; Berge G; Sando SB; White LR; Auestad BH; Witoelar A; Andreassen OA; Ulstein ID; Aarsland D
J Alzheimers Dis; 2016; 50(2):567-76. PubMed ID: 26757188
[TBL] [Abstract][Full Text] [Related]
5. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
6. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
7. Interaction between Apolipoprotein E and Butyrylcholinesterase Genes on Risk of Alzheimer's Disease in a Prospective Cohort Study.
Chuang YF; Varma V; An Y; Tanaka T; Davatzikos C; Resnick SM; Thambisetty M
J Alzheimers Dis; 2020; 75(2):417-427. PubMed ID: 32250307
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
Darreh-Shori T; Siawesh M; Mousavi M; Andreasen N; Nordberg A
J Alzheimers Dis; 2012; 28(2):443-58. PubMed ID: 22012848
[TBL] [Abstract][Full Text] [Related]
9. APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.
Waring JF; Tang Q; Robieson WZ; King DP; Das U; Dubow J; Dutta S; Marek GJ; Gault LM
J Alzheimers Dis; 2015; 47(1):137-48. PubMed ID: 26402762
[TBL] [Abstract][Full Text] [Related]
10. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
Jasiecki J; Wasąg B
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
[No Abstract] [Full Text] [Related]
11. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
13. Association between butyrylcholinesterase K variant and mild cognitive impairment in the Thai community-dwelling patients.
Pongthanaracht N; Yanarojana S; Pinthong D; Unchern S; Thithapandha A; Assantachai P; Supavilai P
Clin Interv Aging; 2017; 12():897-901. PubMed ID: 28603409
[TBL] [Abstract][Full Text] [Related]
14. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.
Whitehair DC; Sherzai A; Emond J; Raman R; Aisen PS; Petersen RC; Fleisher AS;
Alzheimers Dement; 2010 Sep; 6(5):412-9. PubMed ID: 20813342
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
16. Vitamin E and donepezil for the treatment of mild cognitive impairment.
Petersen RC; Thomas RG; Grundman M; Bennett D; Doody R; Ferris S; Galasko D; Jin S; Kaye J; Levey A; Pfeiffer E; Sano M; van Dyck CH; Thal LJ;
N Engl J Med; 2005 Jun; 352(23):2379-88. PubMed ID: 15829527
[TBL] [Abstract][Full Text] [Related]
17. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
18. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
Patterson CE; Todd SA; Passmore AP
Pharmacogenomics J; 2011 Dec; 11(6):444-50. PubMed ID: 20644562
[TBL] [Abstract][Full Text] [Related]
19. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Rogers SL
Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials.
Schneider LS; Raman R; Schmitt FA; Doody RS; Insel P; Clark CM; Morris JC; Reisberg B; Petersen RC; Ferris SH
Alzheimer Dis Assoc Disord; 2009; 23(3):260-7. PubMed ID: 19812469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
